Merit Medical Systems
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Merit Medical Systems sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Merit Medical Systems: 18 sponsored US clinical trials, 5 recruiting.
Merit Medical Systems sponsors 18 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 7 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Venous Occlusion, with 3 trials.
Top-decile sponsor footprint
Merit Medical Systems ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
7 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
18 total, page 1 of 1
WRAP North America
NCT06807099
PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
NCT06422871
PREEMIE: Study for Treatment of PDA in Premature Infants
NCT06587282
Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)
NCT06153667
US Post-Market Surveillance Study of the Surfacer System
NCT05050799
GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)
NCT05818150
The Merit WRAPSODY AV Access Efficacy Study (WAVE)
NCT04540302
Embosphere® PROstate Post Market Study
NCT03527589
Evaluation of the Surfacer System Approach to Central Venous Access
NCT03209050
The STAR™ Tumor Ablation Registry
NCT02419703
EndoMAXX Endoluminal Valve Technology (EVT) Compared to EndoMAXX
NCT02159898
Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)
NCT02225223
Post Marketing Surveillance of the CentrosFLO™ Tunneled IJ Catheter
NCT02349308
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
NCT01789840
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
NCT01387932
HeRO Graft Compared to Permanent Catheters for End Stage Renal Disease (ESRD) Patients Receiving Hemodialysis
NCT01343251
HeRO Vascular Access Device Bacteremia Study
NCT00889564
Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study
NCT00890045
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Where Merit Medical Systems enrollment is open (later-stage tilt)
5 recruiting of 18 indexed (28% open); 7 completed (39%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Venous Occlusion (3 trials), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Merit Medical Systems: open-pipeline peers nationwide
Peers matched on 18 registered trials and 28% open enrollment, not the therapeutic-area sidebar.
Merit Medical Systems sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 trials (± recruiting share)
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors near 28% open enrollment (± trial volume)
- Hanmi Pharmaceutical Company Limited · 28% recruiting · 25 trials
- The University of Texas at Dallas · 28% recruiting · 50 trials
- University of Arkansas, Fayetteville · 28% recruiting · 25 trials
- Massachusetts Eye and Ear Infirmary · 27% recruiting · 73 trials
Related
What to do with this Merit Medical Systems page
18 registered trials is a research-attention snapshot, not an endorsement of Merit Medical Systems or any single study.
- 5 of Merit Medical Systems's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Venous Occlusion is the condition Merit Medical Systems studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Venous Occlusion trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Merit Medical Systems pipeline card: 18 registered trials from official public datasets.Report a data error.